Maze Therapeutics (MAZE) Total Current Liabilities (2024 - 2026)

Maze Therapeutics has disclosed Total Current Liabilities across 3 years of filings, most recently posting $21.2 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $21.2 million, up 14.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $21.2 million (up 14.07% YoY), and the FY2025 annual result was $22.6 million, up 9.11% from the prior year.
• Total Current Liabilities came in at $21.2 million for Q1 2026 at Maze Therapeutics, down from $22.6 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $22.6 million in Q4 2025 to a low of $18.6 million in Q1 2025.
• The 3-year median for Total Current Liabilities is $21.0 million (2024), against an average of $20.8 million.
• Across the five-year window, Total Current Liabilities grew 9.11% in 2025 and gained 14.07% in 2026, its largest moves.
• Maze Therapeutics' Total Current Liabilities stood at $20.7 million in 2024, then grew by 9.11% to $22.6 million in 2025, then slipped by 5.85% to $21.2 million in 2026.
• The last three Total Current Liabilities figures came in at $21.2 million (Q1 2026), $22.6 million (Q4 2025), and $22.1 million (Q3 2025), per Business Quant data.